A study for the effect of EGFR-tyrosine kinase inhibitor in lung cancer with activating EGFR mutation
| Project/Area Number |
22700916
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
SOH Junichi 岡山大学, 岡山大学病院, 助教 (90559890)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | EGFR-TKI阻害剤 / 薬剤耐性 / EGFR遺伝子変異 / EGFR変異 / EGFR-TK1 / 獲得耐性 / FAK阻害剤 / HSO90阻害剤 |
|---|
| Research Abstract |
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) shows good clinical outcome in lung adenocarcinoma patients harboring activating EGFR mutations, but most of them acquire resistance. Investigation of mechanisms of acquired resistance and establishment of new treatment strategy are extremely needed. We performed microarray of miRNAs in acquired resistant cell lines as well as parental cell lines and elucidated miR-200 as a candidate of TKI-resistance related miRNA. We also analyzed the effect of Tae226, an inhibitor for FAK, to find that TAE226 showed significant anti proliferative effect on EGFR-mutant lung cancer with or without TKI resistance in vitro and in vivo.
|
Report
(4 results)
Research Products
(12 results)
-
-
-
[Journal Article]2010
Author(s)
豊岡 伸一, 光冨 徹哉, 宗 淳一, 山本 寛斉, 三好 新一郎
-
Journal Title
肺癌
Volume: 50巻
Pages: 329-341
Related Report
-
[Presentation] Knockdown of EGFR to investigate its therapeutic potential for treatment of non-small cell lung cancers2012
Author(s)
J Soh, K Shien, T Ueno, K Tsukuda, K Suda, T Kubo, M Furukawa, T Muraoka, Y Maki, N Tanaka, H Yamamoto, K Kiura, T Mitsudomi, S Toyooka, S Miyoshi
Organizer
AACR2012
Place of Presentation
シカゴ、アメリカ
Year and Date
2012-04-01
Related Report
-
-
-
-
[Presentation] The anti-tumor effect of TAE226, dual inhibitor of FAK and IGF-IR, on non-small-cell lung cancer with EGFR mutation2010
Author(s)
H Otani, S Toyooka, M Takaoka, M Sakaguchi, T Ueno, H Yamamoto, J Soh, T Kubo, H Asano, K Tsukuda, M Yamane, T Oto, K Kiura, N Huh, Y Naomoto, S Miyoshi
Organizer
AACR2010
Place of Presentation
ワシントンDC、アメリカ
Year and Date
2010-04-19
Related Report
-
[Presentation] 肺癌の分子標的治療 基礎から臨床へ EGFR-TKIの耐性機構とその克服2010
Author(s)
豊岡 伸一, 宗 淳一, 大谷 弘樹, 小林 成行, 久保 孝文, 上野 剛, 青景 圭樹, 山根 正修, 大藤 剛宏, 木浦 勝行, 三好 新一郎
Organizer
第51回日本肺癌学会総会
Place of Presentation
広島
Related Report
-
[Presentation] 、肺癌細胞株におけるTAE226 の変異型EGFRチロシンキナーゼ特異的な不活化作用とその抗腫瘍効果の検討2010
Author(s)
宗 淳一, 豊岡 伸一, 大谷 弘樹, 高岡 宗徳, 阪口 正清, 治田 賢, 久保 孝文, 山本 寛斉, 浅野 博昭, 佃 和憲, 木浦 勝行, 許 南浩, 猶本 良夫, 三好 新一郎
Organizer
第83回日本組織培養学会
Place of Presentation
岡山
Related Report
-
-
